Predictive Biomarker in PD-1/PD-L1 Immune Checkpoint Blockade Therapy

Therapeutic response to PD-1/PD-L1 blockade can be predicted by using this biomarker expressing on cancer associated fibroblast (CAF)


  • There is a high correlation between expression level of this biomarker and therapeutic response rate in anti-PD1 antibody drug therapy for lung cancer patients.
  • This biomarker can discern non-responders from responders before immune checkpoint blockade therapy. It reduces significant side-effect cases and medical expenses in treatment of non-responders.

Background & Technology

  • Immune checkpoint PD-1/PD-L1 inhibitors, such as Nivolumab and Pembrolizumab, block receptor-ligand interactions between immune and tumor cells and inhibit immune-suppressive signals in a wide spectrum of malignancies. Immune checkpoint blockade has been approved in advanced melanoma, renal cell cancer, non-small cell lung cancer, relapsed refractory Hodgkin’s lymphoma, and urothelial cancer. Adverse effects and existence of non-responders, however, can limits our use of these agents. To help discern responders from non-responders to the treatment, PD-L1 immunohistochemistry was developed. Despite PD-L1 assays, however, some of patients that are considered to be PD-L1-negative will still respond, while some of PD-L1 positive patients will not respond to the treatment. Therefore, additional predicting biomarkers are required for accurately predicting response to immune checkpoint blockade.
  • We identified a novel biomarker that is expressing on the CAF in tumor tissue from responder patients (right figure). In comparison to PD-L1, the accuracy of this prediction biomarker is better, especially in identification of non-responders.


Marker_Immuno-oncology 1

Data & Publication

  • There is a correlation between the marker expression level and the Disease Control Rate and Objective Response Rate (ORR) assessed by iRECIST, although the PD-L1 expression level (TPS) indicates no correlation with ORR on the same samples from 52 patients.
  • There is also a correlation between the marker expression level and the Overall survival rate of the patients with PD-1/PD-L1 blockade treatment.


Marker_Immuno-oncology 2
 Marker_Immuno-oncology 4




Dr. Atsushi Enomoto, Dr. Yuki Miyai (Nagoya University)

Product No:TP-00783


Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name


Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.


Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.